<DOC>
	<DOC>NCT00254787</DOC>
	<brief_summary>The purpose of the study is to compare the safety and tolerability of IR (Immediate-Release) quetiapine in a rapid escalation scheme with to the current approved label titration.</brief_summary>
	<brief_title>Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Men and women age ≥18 to ≤65 years with acute schizophrenia Provision of written informed consent prior to enrolment Meeting the criteria for any other (than schizophrenia) psychotic disorder not in full remission, concomitant organic mental disorder or mental retardation Patients with substance dependence Female patients who are pregnant, lactating or at risk of pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>